AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
382.71B
Market cap382.71B
Price-Earnings ratio
105.80
Price-Earnings ratio105.80
Dividend yield
3.14%
Dividend yield3.14%
Average volume
5.42M
Average volume5.42M
High today
$220.00
High today$220.00
Low today
$214.25
Low today$214.25
Open price
$216.35
Open price$216.35
Volume
2.65M
Volume2.65M
52 Week high
$244.81
52 Week high$244.81
52 Week low
$180.25
52 Week low$180.25

Stock Snapshot

With a market cap of 382.71B, AbbVie(ABBV) trades at $216.62. The stock has a price-to-earnings ratio of 105.80 and currently yields dividends of 3.1%.

On 2026-05-22, AbbVie(ABBV) stock moved within a range of $214.25 to $220.00. With shares now at $216.62, the stock is trading +1.1% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 2.65M, compared to an average daily volume of 5.42M.

The stock's 52-week range extends from a low of $180.25 to a high of $244.81.

The stock's 52-week range extends from a low of $180.25 to a high of $244.81.

ABBV News

TipRanks 5h
AbbVie reports positive CHMP opinion for Maviret

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval...

Nasdaq 8h
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market

Key Points AbbVie's stable business makes it an ideal pick during uncertain times. The stock offers an attractive dividend yield, track record of dividend inc...

Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
Simply Wall St 2d
Assessing AbbVie Valuation After Recent Share Price Movement And Rich Earnings Multiple

AbbVie (ABBV) is back on investors’ radar after a recent move in its share price, with the stock closing at US$212.30. That shift has sharpened the focus on its...

Assessing AbbVie Valuation After Recent Share Price Movement And Rich Earnings Multiple

Analyst ratings

73%

of 33 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

More ABBV News

TipRanks 2d
AbbVie’s NAAVIGATE Trial Targets One-Time Gene Therapy for Diabetic Retinopathy

Abbvie (ABBV) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel...

TipRanks 3d
AbbVie Earnings Call Highlights Growth Amid Transition

Abbvie ((ABBV)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful inv...

Seeking Alpha 3d
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial

UCB (UCBJY) announced on Tuesday that its biologic medicine Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriati...

UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.